Amgen on Soliris: Low patient population but high biosimilar potential
The high cost of Alexion’s ultra-orphan disease MAb Soliris (eculizumab) drove Amgen’s decision to develop a biosimilar version, says SVP of Global Development Elliott Levy. Soliris (eculizumab) is an approved treatment for orphan diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypica ...
Contract research organization (CRO) PPD will expand its biologics capabilities in Athlone, Ireland to include cell and gene therapy analytical t ...
The US FDA observed potentialmold contamination and deficient aseptic processes during an inspection at Pfizer’s fill/finish facility in McPh ...
Changing policies in China bring opportunities for foreign CDMOs says Lonza, which is opening a biologics facility in Guangzhou, supported by G ...
Sanofi will cut 750 jobs in France but says it remains committed to biologic and vaccine manufacturing investments totaling €700 million ($800 ...
Recent Tweets
-
Lonza to biomanufacture in China with a little help from GE https://t.co/lxjX7eCuHQ
1 day ago
-
RT @Dan5tanton: Belgian CDMO MaSTherCell will be able to manufacture about 1,000 batches a year through the expansion, doubling cap… https://t.co/498hKeIUZU
7 days ago
-
RT @Dan5tanton: Truxima becomes the 15th US biosimilar, and the first version of Rituxan (rituximab). Settlement agreement with Roc… https://t.co/FXrcrc5cb5
2 weeks ago
-
RT @ZacharyBrennan: wow. huge news. https://t.co/QRKa43EG0j
2 weeks ago
Trending
Upstream Processing
Cell Culture Scale-Up in Stirred-Tank Single-Use Bioreactors
Analytical
eBook: Using Modern In Situ Analytics and PAT for Automated Feedback Control of Critical Process Parameters
Analytical
Multitiered Automation for Improved Efficiency of Bioprocess Analytics
Business
Partnerships in Immunotherapy: Working Together to Take Cancer Treatment to the Next Level